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Recent achievements in basic genomic science are widely heralded
as carrying great clinical potential – and therefore in need of translation-
al support. Knowledge on the molecular mechanics and pathways of
disease should contribute to more tailored forms of individual medical
care, but it is widely acknowledged that this cannot happen without
considerable investment in bringing advances from the laboratory
‘bench’ to the clinical ‘bedside’ (Niederhuber, 2010). In particular, the
detailed understanding of human biological complexity at the molecu-
lar level is expected to contribute to further patient stratiﬁcation and
the delivery of care tailored to biologically differentiated patient groups.
Rooted in genomics and systems biology, the future ofmedicine is often
sketched in terms of the preservation of individual health, rather than
treating disease in the aggregate population (Hood and Friend, 2011).
Yet to arrive there, various technical and social challenges to translation
need to be addressed to ‘bridge the gap’ between bench and bedside.
In recent years, the intricate complexity of such ‘bridging’ has in-
creasingly been recognized, and translation reconsidered as a two-
way road (Marincola, 2003) that should involve broader communities
around bench and bedside (Cohrs et al., 2015). The challenge of making
scientiﬁc knowledge beneﬁcial for overall population health has conse-
quently been deﬁned as a continuum of various translational phases –
especially in the context of genomics (Khoury et al., 2007; Schully and
Khoury, 2014). For translation to proceed through the various phases,. This is an open access article undermedical researchers call for investments in all of them, ranging from
translation of basic science to clinical application (T1); on to evidence
based practice guidelines (T2); evaluation in practice (T3); and popula-
tion level evaluation of health outcomes (T4), respectively. Yet even
while this approach to translation acknowledges the work that remains
to be done for novel diagnostics or therapeutics to contribute to popula-
tion health, the multi-phase model of translation remains attached to a
technical (i.e. evidence-based) understanding of the problem (for a
broader critique around this point, see (Van der Laan and Boenink,
2015)). Research in the social sciences, by contrast, has shown how
translation efforts are always closely entangled with a broader social
context that shapes howmedical innovation, its application and its inte-
gration in health care delivery arrangements take shape (Vignola-
Gagne and Biegelbauer, 2013). Moreover, the various phases of transla-
tion may relate and unfold very differently considering both the social
conﬁguration of research and clinical care and the speciﬁc domains of
genomic research and medicine in which these efforts unfold
(Gardner andWebster, 2016; Merriman andMolina, 2015). A more de-
tailed understanding of speciﬁc sociocultural understandings of health
and diseases and social preferences vis-à-vis the incorporation of partic-
ular novel (genomic) technologies in health care distribution is there-
fore required to fully understand how translation may beneﬁt
population health (Aarden et al., 2010).
This paper aims to contribute to a more detailed understanding of
the intersections between social and technical dimensions of translation
by investigating how genomic advances are delivered to populations in
different health care contexts. It explores this question through a com-
parison of services available for risk assessment and follow-up forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the United Kingdom. Applications of genomics in the oncological do-
main are at the forefront of translating genomics from research to med-
ical care (Dolsten and Soegaard, 2012; Bombard et al., 2013), both in
terms of genomic approaches to cancer risks (related to germlinemuta-
tions) and the development and characteristics of tumors (somatic mu-
tations). While germline and somatic approaches to cancer genomics
are different, they share certain characteristics of interest from the
viewpoint of translation. Both (should) allowmore sophisticated classi-
ﬁcation of disease (risk) into distinct subcategories and earlier interven-
tion more tailored to affected sub-populations (Bydoun et al., 2014). At
the same time, a focus on familial cancer risks allows us to see how uses
of genomics are established as routines, how the limits of molecular
technologies are confronted (since only around 30% of familial breast
cancers has a known genetic background (Shiovitz and Korde, 2015;
Foulkes, 2008)), and how technicalities of risk stratiﬁcation intersect
with the social dimensions of health care infrastructures to bring geno-
mics to the population. Approaching translation of genomic technolo-
gies to patient care from this vantage point provides insight into the
mutual inﬂuence between risk classiﬁcation and health care delivery in-
frastructures and the social and technical dimensions of translation in
distinct contexts.
2. The importance of health care infrastructure
The technocratic nature of much of the translation discourse – par-
ticularly in the domain of bench-to-bedside (Woolf, 2008) – reﬂects a
‘technological imperative’ that suggests that new technologies will by
deﬁnition reshape health care. Yet various studies of the development
of technologies in health care and beyond have shown how these com-
monly develop in close interaction with their social environment, with
both technology and society coproducing each other (Jasanoff, 2004).
In the context of complex health care environments that both shape
and are shaped by advances in medical technology, a framework that
understands the roads new technologies travel to become available to
patients in particular clinical settings may be fruitfully understood in
termsof health care infrastructures. This notion of infrastructure expands
on Parthasarathy's study of ‘architectures’ for genetic testing for breast
cancer in the United States and the United Kingdom (Parthasarathy,
2005). While she helpfully notes how structures of regulation, technol-
ogy development and health care delivery inﬂuence how genetic tests
are delivered in distinct forms to different segments of the population
in these countries, the notion of infrastructuremore explicitly considers
thewider context of genetic tests and themore extensive range of issues
that characterize ‘translation’. These issues include culturally speciﬁc re-
sponses to howmedical knowledge is made and incorporated in health
care, which conﬁgurations of actors and mechanisms are involved in
evaluating new diagnostics and therapeutics, how they are distributed,
etc. (Daemmrich, 2004). These diverse socio-cultural elements collec-
tively shape an infrastructure for translating genomics to patient care,
a process that involves a balancing act between full development of
technological possibilities and improving health for as large a part of
the population as possible (Aarden et al., 2011).
The infrastructures that shape the translation of genomic technolo-
gies to health care delivery are highly context-speciﬁc. A powerful
way to gain insight into the role of infrastructures in the later phases
of translation is therefore to compare between different infrastructural
environments. The comparison in this paper includes three Western-
European countries – Germany, the Netherlands, and the United King-
dom – that are similar in many ways, but differ in several respects
that are important to our purpose here. In particular the organizational
structure of health care delivery and sociopolitical responses to ad-
vances in medical applications of genomics color the ways familial un-
derstandings of breast cancer have been adopted in health care
delivery. We will encounter some of these differences in detail when
discussing the infrastructures for delivering familial breast cancerdiagnostics below, yet in broad terms we may identify two axes of dif-
ference. On the one hand, health care delivery in Germany and the
Netherlands is based on (social) health insurance, where individuals
pay a premium to an insurance company that purchases medical ser-
vices on behalf of their collective membership. In the UK health care is
funded through general taxation, with funds for the National Health
Service (NHS) redistributed to regional purchasing authorities (Van
der Zee and Kroneman, 2007). These different structures affect how ﬁ-
nancial resources are distributed, how decisions about reimbursement
are made, and who is involved in making health care policies (Van
Hoyweghen, 2014). At this structural level, Germanymay further be dis-
tinguished from the other two countries by having a so-called ‘double
structure’ of physicians employed by hospitals and those that are self-
employed (a differentiation that roughly overlaps with the delivery of
inpatient and outpatient care). Where it comes to political responses
to the advent of genomics, the Netherlands and the United Kingdom
may be grouped together as well, since in both countries the health
ministries developed elaborate strategies for integrating genomics in
health care. For various reasons, no strategy of that sort was developed
in Germany. As wewill see, these andmore speciﬁc characteristics con-
stitute the infrastructures that give shape to the translation of genomics
to routine medical interventions – affecting both the social and techni-
cal conﬁguration of genomics' contributions to population health.3. Developing a comparative perspective
This paper deliberately takes a step back from the frontier of devel-
opments in cancer genomics to focus on the assessment of hereditary
breast cancer risks and genetic testing for BRCA mutations in three Eu-
ropean countries. It thereby seeks to answer a question that has re-
ceived relatively little attention in discussions on how the translation
of genomic knowledge can contribute to the improvement of popula-
tion health. While various social scientists have pointed to the changes
that affect research communities, clinical practitioners and the relations
between genomics research and the attribution of meaning to genomic
ﬁndings in the clinic (Rabeharisoa and Bourret, 2009;Harvey, 2011), the
broader infrastructures for health care delivery, access and reimburse-
ment of genomic technologies remain more obscure (Aarden, 2016).
To address this void, the paper neither seeks to address only the cutting
edge of advances in the ﬁeld, nor does it seek to be comprehensive with
regard to contributions genomics has made to understanding the com-
plexity of breast cancer predispositions and progression of disease. The
paper instead provides empirical evidence for the complex intersections
between social and technical dimensions of how diagnostics are distrib-
uted. On that basis it proposes away to explore the social dimensions of
translation from, as it were, bedside to health care infrastructures. We
may thereby gain insight into the establishment of health care delivery
routines and how some of these routines may affect further incorpora-
tion of genomics in health care delivery in the future.
The paper focuses on the establishment of routines for the delivery
of diagnostics and follow-up services for familial breast cancer risks in
the ﬁrst decade of the present century. Empiricalmaterial was primarily
collected between 2005 and 2010, complemented with a short litera-
ture reviews to assess whether guidelines and standards for risk assess-
ment have changed to a signiﬁcant degree since the initial data
collection was completed. While this should not imply that no impor-
tant developments in breast cancer genomics have taken place since,
medical evidence suggests that no radical change has taken place in
the main risk categories (based on family history and identiﬁable gene
mutations; (Shiovitz and Korde, 2015)). Moreover, taking a few years
of distance allows us to clarify the origins of routines in speciﬁc contexts,
without having them obscured by ‘incomplete’ evidence from recent
and experimental approaches that are highly prevalent in health care
systems' attempts to grapple with the signiﬁcance of genomics for the
future of medicine.
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through the analysis of relevant documents and interviews with medi-
cal professionals and public ofﬁcials involved in the integration of geno-
mics in health care delivery. The documents, which include regulations,
standards and guidelines as well as opinion articles and perspectives in
medical journals in all three countries, were identiﬁed through searches
of online databases of regulations and national medical journals. Inter-
view respondents were identiﬁed either from these publications, by
contacting relevant organizations (ministries, medical professional or-
ganizations – both generic and specialized in relevant ﬁelds - national
expertise centers, etc.), and by asking respondents for further sugges-
tions (so-called snowball sampling). A total number of 33 professionals
was interviewed; 11 of them inGermany, 9 in theNetherlands and 12 in
the United Kingdom. Materials from both document analysis and inter-
views were coded for particular themes of interest such as risk classiﬁ-
cation, indications for genetic testing, follow-up procedures, availability
and distribution of services, etc. Results were constantly compared
across national borders to gain more pronounced insight into national
speciﬁcities. While the approaches in each of the countries presented
an internally coherent (even if sometimes paradoxical) logic, thediscus-
sion below structures the presentation ofmaterials along thematic rath-
er than national lines – in order to advance our insight into the roles
distinct infrastructures play in, respectively, classifying familial risks,
applying molecular genetic diagnostics, and providing subsequent fol-
low-up and prevention. In the ensuing discussion and conclusion sec-
tion, we will address the social mechanisms of translation these
countries share, their different contextual manifestations and what
this implies for the social and technical shape translation takes in cancer
genomics and beyond.
4. Translation infrastructures for risk assessment
The questionwhether and how hereditary factors play a role in can-
cer has a long history that predates scientiﬁc and technological capabil-
ities for understanding why cancer is more prevalent in some families
than in others. In more scientiﬁcally and clinically useful ways, familial
dimensions of cancerwere uncovered from the 1970s onwards; initially
through registration and the analysis of statistical correlations, and
through the identiﬁcation of direct links between genetic mutations
and increased likelihoods of developing the disease from the 1990s on-
wards (Mukherjee, 2010). Despite these advances, the clinical adoption
of knowledge about correlations between gene mutations and cancer
remains a challenge due to the fact that (for most cancers) not all muta-
tion carriers develop the disease and vice versa, not all cases of cancers
(even those clustering in families) can be accounted for inmolecular ge-
netic terms. As wewill see, a core issue to the translation of genomics to
health care is therefore how to account for this plurality of risks. Usually,
the ﬁrst step is therefore risk classiﬁcation based on family history
analysis.
4.1. Classifying familial risks
Even though health care services in these three countries are based
on shared scientiﬁc insight into increased likelihoods of cancer on the
basis of family history and genetic mutations, categories and criteria
used in clinical practice are remarkably different. Not only are classiﬁca-
tory boundaries drawn differently, but approaches to risk assessment
are shaped by the distinct health care infrastructures in ways that are
deeply incongruent. Not only are the risk categories and criteria for as-
sessment different or are guidelines developed by vastly different orga-
nizations, even the purposes of risk assessment in terms of the forms of
risk they seek to distinguish are fundamentally different.
To begin, risk assessment in theNetherlands is to a large degree con-
tinuous with family classiﬁcations that preceded the advent of genetic
testing. Since the early 1980s, an independent organization called
StOET (a Dutch acronym that stands for Society for the Detection ofHereditary Tumors) runs a registry of familial cancers and, in collabora-
tion with the Dutch Society of Clinical Geneticists, produces diagnostic
guidelines for assessing individual risks (Stichting Opsporing Erfelijke
Tumoren and Vereniging Klinische Genetica Nederland Werkgroep
Klinische Oncogenetica, 2010). This organization was originally funded
by theMinistry of Health, but currentlyﬁnances its activities through di-
rect payment for services it delivers to hospitals.
Current guidelines for risk assessment no longer primarily use statis-
tical percentages and categories (as they used to), but instead describe
scenarios to identify womenwho should receive additional monitoring,
those who should be referred to a specialist geneticists and distin-
guishes betweenmoderate andhigh risks for thepurpose ofmonitoring.
The group eligible for additional monitoring (see also Section 4.3) con-
sists ofwomenwhohave a lifetime risk that ismore than twofold that of
the general female population. This group includes women who have
two ﬁrst-degree relatives diagnosed with breast cancer before the age
of 50, or womenwho have a ﬁrst or second degree relativewith ovarian
cancer and a ﬁrst or second degree relative diagnosed with breast can-
cer before the age of 60. The guideline for referral to a genetics specialist
additionally includes women diagnosed with breast cancer before the
age of 35, womenwith a brother/father with breast cancer and a female
relative with breast or ovarian cancer on the same side of the family, or
with three ormore ﬁrst or second degree relativeswith breast cancer, at
least one of which was diagnosed before the age of 50 (for more details
on these guidelines see (Stichting Opsporing Erfelijke Tumoren and
Vereniging Klinische Genetica Nederland Werkgroep Klinische
Oncogenetica, 2010)).
For follow-up, the Dutch guidelines reﬁne these categories and
distinguish between a category of moderately (2–3 times population
risk) and strongly (3–4 times population risk) increased risks (with-
out specifying how to distinguish between these two types of risk),
referring the former to a general practitioner (GP) for monitoring
purposes, and the latter to a specialist physician. Furthermore, the
Dutch guidelines are the only ones making a sharp distinction
between what is called familial risk (based on family history assess-
ment) and hereditary risk (based on the identiﬁcation of a genetic
mutation). As we will see below, this distinction in terms of the pres-
ence or absence of a genetic mutation has particular consequences in
the context of follow-up.
The guidelines in the Netherlands are produced by organizations
that specialize in genetics and hereditary tumors, while a national stan-
dard setting body for all of health care issues similar instructions in the
United Kingdom (technically only England and Wales, although inter-
view respondents argued that Scotland and Northern Ireland largely
concur). This organization, theNational Institute for Health and Care Ex-
cellence (NICE) has issued several revisions of its guidelines for familial
breast cancer. The most recent version appeared in 2013; according to
NICE regulations, the guideline is up for revision again in 2017. The
guidelines are written by a committee of experts in a particular ﬁeld
and are supposed to serve as best practice standards for health care
throughout the country. NICE guidelines are also developed as a man-
agement tool for the health service as a whole, especially in comparison
to the guidelines developed by more specialized professional organiza-
tions in the Netherlands and Germany.
The familial breast cancer guideline consequently links distinct risk
categories explicitly to different segments of theNational Health Service
(NHS) (NICE, 2013). It distinguishes betweenwomen at or near popula-
tion risk (b17% lifetime risk at age 20, b3% between age 40 and 50),who
should be seen by their GP and in the national population screeningpro-
grambetween the ages of 50 and 70;women atmoderate risk (between
17 and 30% lifetime risk, 3–8% between 40 and 50), who should be
attended to by a secondary care specialist like a surgeon or radiologist
for regular surveillance; and high risk women (lifetime N30%, N8% be-
tween 40 and 50; including BRCA and TP53 mutation carriers) who
should be referred to a tertiary care specialist in genetics. As we will
see, this particular conﬁguration and distribution of risk categories has
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monitoring and early detection services in the UK.
Compared to the Netherlands and the United Kingdom, the diagnos-
tic strategy in Germany has a different aim. Rather than to stratify the
likelihood of developing breast cancer for all women on the basis of
their family history, initial risk assessment in Germany is oriented to-
wards distinguishing women who do or do not qualify for a genetic
test. This is a result of the recommendations of two leading medical or-
ganizations in Germany– the Federal Chamber of Physicians and the So-
ciety for Human Genetics – to proceed carefully after the identiﬁcation
of the BRCA genes in the 1990s (Bundesärztekammer, 1998;
Gesellschaft für Humangenetik, 1995). In response to these guidelines,
several university hospitals set up a consortium to develop best prac-
tices for genetic testing (see Section 4.2), an important element of
which was to identify women for whom testing would have clinical
value. Similarly, a guideline for risk assessment developed by German
cancer organizations and the cooperative association of medical scien-
tiﬁc associations AWMF recommends genetic counseling and testing
in specialized centers (meaning those in the consortium) for women
meeting one of several criteria (Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen Fachgesellschaften, 2012).
This so-called S-3 guideline (which have the highest level of conﬁ-
dence in the related evidence base) thus equally focuses onways to dis-
tinguish betweenwomenwho should and thosewho should not receive
a genetic test. Criteria include the presence of three or more women in
the family diagnosedwith breast cancer, one ormorewomendiagnosed
with breast cancer before the age of 35 or two or more women diag-
nosed with ovarian cancer (scenarios that are virtually identical with
those used in the Netherlands). Furthermore, on its website the consor-
tium provides a form to medical professionals that allows them to tick
boxes for the presence of breast and ovarian cancers in ﬁrst degree rel-
atives and further relatives in the paternal or maternal line. Ticked
boxes are linked to certain point values, which may be added up and,
when the score is three or higher, indicate a need to refer a woman
to one of the consortium centers (see http://www.konsortium-
familiaerer-brustkrebs.de/medien/user_upload/8_Checkliste.pdf;
accessed 14 July 2016).
Any further risk assessment on the basis of family history is second-
ary to genetic testing, and only applied to womenwho have undergone
a genetic test. In case that test comes back inconclusive or negative,
women are offered breast monitoring on the basis of their statistical
risk – which has to be N30% lifetime risk of developing breast cancer
or a 20% risk of carrying an (as yet unidentiﬁable) gene mutation
(Zylka-Menhorn, 2013).
4.2. Applying molecular genetic diagnostics
The German Consortium for Familial Breast and Ovarian Cancer
(www.konsortium-familiaerer-brustkrebs.de, accessed 14 July 2016)
consists of (presently) seventeen university clinics that joined together
to develop a joint concept for genetic testing, monitoring and further
studies on the signiﬁcance and implications of genetic testing for breast
cancer predispositions. The consortium started out with ﬁnancial sup-
port from the German Cancer Society, but was incorporated in regular
health care reimbursement under Germany's statutory health insurance
within a few years (Schmutzler et al., 2006). Yet the reimbursement of
patient care through the collective sickness funds that cover the major-
ity of medical expenses for German patients was only possible due to a
recent amendment to health care regulation in Germany. Only since
2004 can hospitals provide certain highly specialized or experimental
outpatient procedures with funding from public health insurance
funds. This includes the services provided by the consortium.
The role of regulatory change in facilitating the establishment of the
consortium – or at least the accessibility of its services for the average
German woman – points to the particular status of clinical genetics in
Germany. Whereas clinical genetics was originally established in closeassociation with research in academic hospitals, its services of genetic
counseling and testing are in principle outpatient procedures - roughly
distinguished by the fact that they do not require overnight admission -,
which are traditionally provided by self-employed, ‘private’ physicians
(not to be confused with privately ﬁnanced medical care). Themajority
of genetic tests in Germany is consequently provided in independent
genetics clinics. Similar to the academic consortium, these clinics are
primarily oriented towards offering genetic testing, but employ criteria
unlike those proposed by the consortium. In interviews, private geneti-
cists presented themselves as service providers for their patients –
women concerned about their risk – and they considered an offer
of genetic testing legitimate if it could help alleviate a woman's
concerns. Consequently, private geneticists do not necessarily limit
genetic testing to women with a family history indicating a signiﬁ-
cant increase in risk. Moreover, despite the principle of cost-effec-
tiveness that is central to health care ﬁnancing in Germany,
insurance funds have no instruments to restrict this practice, since
the catalogue for reimbursement of outpatient care states that any
genetic test prescribed by a qualiﬁed professional ought to be reim-
bursed, regardless of indication – a point that is of great importance
for medical professional's sense of autonomy.
The contrast between this German practice and the situation in the
Netherlands is perhaps the greatest, since genetic services in the latter
are by law restricted to eight centers associatedwith academic hospitals
(see http://wetten.overheid.nl/BWBR0014594/2009-03-05, accessed
14 July 2016). Only those eight centers are allowed to provide genetic
counseling and perform genetic tests.While the aforementioned guide-
lines for familial cancer risk assessment do not provide distinct criteria
for genetic testing, a genetic test is an option for all women who do
qualify for referral to a genetics clinic. Yet the forms of care offered at
a genetics clinic may also consist of one or more counseling sessions
only. An earlier version of the diagnostic guideline prescribes DNAdiag-
nostics when there is a N 10% chance of ﬁnding a BRCA 1 or 2 mutation
(STOET and Vereniging Klinische Genetica Nederland Werkgroep
Klinische Oncogenetica, 2005) – although clinicians indicated in inter-
views that they took this number as a rule of thumb rather than a strict
line and that they used various calculationmethods, the results ofwhich
they would synthesize on the basis of experience and their tacit beliefs
about accuracy of the various methods. In terms of reimbursement, in-
surance companies and the Dutch Society of Clinical Genetics drew up
an agreement in 1995 that still largely applies today, despite reforms
to the Dutch insurance and health care ﬁnancing structures in the inter-
im. According to this agreement, genetics clinics can bill either simple
(one counseling session) or complex consultations (anything more
comprehensive), although material costs of e.g. laboratory procedures
are listed independently.
As indicated before, the Dutch guidelines further distinguish be-
tween familial and hereditary cancer risks on the basis of the proven
presence of a BRCA mutation. While clinicians we interviewed
questioned the signiﬁcance of this distinction in biological and clinical
terms, it does have consequences for the forms of follow-up offered to
individual women at risk, as we will see below.
This sharp distinction between women at a statistically high risk
with orwithout amutation stands in stark contrastwith the recommen-
dations by NICE in the UK, where the follow-up services for these two
groups are largely the same. This may perhaps be related to the limited
availability of genetic testing for BRCA mutations within the NHS. Al-
though the Department of Health committed to solid establishment of
genetic services in the NHS in the context of a policy strategy for genetic
medicine issued a few years after the completion of theHumanGenome
Project (Department of Health, 2003), breast cancer charity Break-
through Breast Cancer published a report only a few years later that
reﬂected critically on the availability of genetic diagnostics and the
time between testing and availability of results (Breakthrough Breast
Cancer, 2006). Geneticists shared the report's observations in inter-
views, and often gave additional examples of problems with genetic
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in order to reduce costs.
Concerns about the precarious status of genetic testing for breast
cancer predispositions in theNHS are reﬂected in Breakthrough's subse-
quent campaign to improve service delivery. On its website the organi-
zation therefore takes credit for some of the changes made to NICE's
familial breast cancer guidelines in its most recent revision (see http://
breastcancernow.org/news-and-blogs/blogs/changing-the-policy-on-
genetic-tests-for-breast-cancer). As of 2013 NICE recommends the use
of carrier probability scores to establish whether women at risk should
be offered genetic testing. The guideline further reduces the threshold
for such an offer from a 20% of ﬁnding a mutation to only 10% and ex-
tends this advice to also include women with no clear family history
or no relativewith diagnosed breast cancerwho can be tested ﬁrst. It re-
mains to be seen whether these changes in recommendation do in fact
improve the availability of genetic testing, due to particularities of
health care ﬁnancing in the UK, which we encounter in more detail in
the next section.
4.3. Providing follow-up and prevention
For women identiﬁed to be at increased risk of developing breast
cancer due to their family history or a genetic mutation, few options
to actually prevent cancer exist. One of the more radical options is pro-
phylactic surgery to remove breast tissue or ovaries, but this is only rec-
ommended for a small minority of women at risk. Beyond that, intense
monitoring of breast tissue through (self-)examinations, mammogra-
phy andMRI is recommended in all three of the countries, but to differ-
ent degrees. These forms of monitoring are often complementary to
population breast screening offered to women over the age of ﬁfty in
each of these countries. Monitoring guidelines for hereditary risks
often do include referral to the screening programs as well as additional
monitoring at earlier ages.
The various follow-up options are most extensively described in the
NICE guideline in the UK, which distinguishes betweenwhat physicians
should actively offer, should consider as options and should not offer to
different categories of women (NICE, 2013). To give only one example,
annual mammography should be offered to (among others) women at
moderate or high risk between the ages of 40 and 49; be considered
for women aged 30 to 39 with a BRCA 1 or 2 mutations; and not be of-
fered to women aged 29 or under. For the latter age group, MRI is rec-
ommended only for women who have a proven TP53 mutation or
N30% likelihood thereof. These recommendations apply to women
without a personal history of breast cancer; more stringent recommen-
dations apply to women who have (had) the disease. For most women
over the age of 50, the guidelines recommend participation in the pop-
ulation screening program (including those over 70 with a BRCAmuta-
tion) and more regular screening for e.g. women with a TP53mutation.
The guideline further speciﬁes the criteria for offering prophylactic sur-
gery and recommends prescriptions of Tamoxifen for ﬁve years for cer-
tain groups of women.
But even though the guideline indicates that women attended to in
secondary care settings such as breast care centers or family history
clinics should receive access to monitoring, it is in exactly this context
that British clinicians see the limitations of NICE guidance. As several
of them indicated in interviews, NICE guidelines aim to set standards
but come with neither formal power nor ﬁnancial incentives to force
implementation. Since most funding for the NHS is allocated to particu-
lar medical services by regional NHS authorities, there are considerable
regional differences in available resources and hence availability of the
recommended interventions. This problem is especially attributed to
secondary care physicians who supposedly prefer to use their limited
resources for mammography screening for women referred with sus-
pect results from the population screening program over women with
raised familial risks (although this may have changed in recent years,
since a study conducted with the exact purpose to assess the efﬁcacyof mammography for women aged 40–49 with increased risk, spon-
sored by Cancer Research UK, suggests such monitoring reduces breast
cancer mortality; see (FH01 Collaborative Teams, 2010)).
While the problem in the United Kingdom is thus rooted in the in-
sufﬁcient funds available for implementing early detection recommen-
dations, the issue appears to be more fundamentally about what
appropriate medical care is in Germany. The aforementioned S3 guide-
line for breast cancer care recommends breast examinations and ultra-
sound at six month intervals, and annual mammography and MRI from
the age of 25, or ﬁve years before the earliest case of breast cancer in the
family, onwards (Arbeitsgemeinschaft der Wissenschaftlichen
Medizinischen Fachgesellschaften, 2012). In linewith the general orien-
tation towards genetic breast cancer risks in Germany, these recom-
mendations apply to women with a BRCA mutation or a risk N30% or a
mutation chance N20%. In addition, only mutation carriers should be of-
fered prophylactic mastectomy and be recommended to undergo pro-
phylactic oophorectomy around the age of forty. All of these forms of
early detection and prevention are clustered in the seventeen consor-
tium clinics; private geneticists are said to recommend these options
primarily when they themselves have established their clinic in a con-
glomerate of private clinics that include radiologists and/or surgeons
who can offer these procedures.
But even though this is what medical professional organizations ad-
vise, several clinicians indicated that insurance funds sometimes refuse
to reimbursemonitoring – as well as genetic testing. The arguments in-
surance funds use to reject reimbursement of breastmonitoring and ge-
netic testing follow the same logic and refer to the central principle of
cost-effectiveness in German health care. In both cases, the funds
argue, there is no speciﬁc clinical indication to perform amedical proce-
dure – a laboratory test or clinical examination. Insurers argue that the
intervention is then a form of generic screening for which efﬁcacy is not
scientiﬁcally established and insurers carry no ﬁnancial responsibility.
While physicians claim that this argument relies on amisunderstanding
of genetic diagnostics and preventive medicine, a conviction shared by
the majority of insurance funds and their association, these examples
suggest that in individual cases women may not get access to the
forms of diagnostics and preventive measures recommended for
them. This is a problemnot exclusive to Germany, although the discrep-
ancies between recommendation and delivery take different shapes
elsewhere.
Still different are the recommendations for follow-up in the Nether-
lands, where each risk category gets its own set of recommendations
(Stichting Opsporing Erfelijke Tumoren and Vereniging Klinische
Genetica Nederland Werkgroep Klinische Oncogenetica, 2010).
Women with a moderately increased risk should receive an annual
mammography through their GP between the ages of 40 and 50 and
participate in population screening until the age of 75. With a strongly
increased risk, women should receive annualmammography and breast
examinations from a specialist physician and subsequently participate
in the screening program until the age of 75. For both categories, in
cases where breast cancer was diagnosed at very young age in the fam-
ily, the guideline further suggests monitoring may start at age 25, al-
though no mammography should be offered before the age of 30. For
women with a hereditary (i.e. genetically conﬁrmed) risk and their fe-
male relatives who have not been tested, breast examinations and
MRI should start at age 25 and MRI and mammography at age 30. Be-
tween ages 60 and 75 these women should also participate in the
screening program. Starting at age 35 these women should further be
offered various gynecological examinations for early detection of ovari-
an cancer (although, the guideline adds, women should be counseled
that the chance of actual early detection is small). In addition, mutation
carriers should be advised to consider prophylactic mastectomy from
age 25 onwards, and prophylactic oophorectomy from age 35–40 for
BRCA1 and 40–45 for BRCA2, respectively. The various preventive inter-
ventions should be offered in interdisciplinary settings in university
hospitals, called Outpatient Clinics for Hereditary Tumors.
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for strongly increased familial and hereditary risks, especially with re-
gard to the different settings in which these services should be provid-
ed. While they are generally positive about the efforts to establish
integrated services for mutation carriers, they argue that similar mea-
sures should be taken for the highest risk category that does not have
a demonstrable genetic predisposition. According to clinicians, these
women also carry a considerable risk of developing cancer, but since
they are supposed to be monitored in their own local hospitals it is dif-
ﬁcult to follow up on whether they actually receive the forms of moni-
toring that are recommended for them. Nevertheless, it is not an
option to include these women in the specialized outpatient clinics,
since their number is about three times that of the mutation carriers
and university hospitals do not have the budget to see such large num-
bers of women at risk in that particular setting. Geneticists are therefore
worried about the fate of these women.
The fragmentation of services provided to women with similar sta-
tistical risks consequently shows howmeasures to promote translation,
or the incorporation of genomics in routine health care, are negotiated
with the constraints of existing health care infrastructures and re-
sources. As a consequence, the contribution of translational efforts to
population health is always contested and incomplete, excluding differ-
ently constituted segments of the population in different contexts.
5. Discussion and conclusion
In the preceding discussion we have seen how insights into the cor-
relation between family history, genetic mutations and individual
breast cancer risk was translated into the delivery of diagnostic services
and follow-up in distinct ways in Germany, the Netherlands and the
United Kingdom. Despite the differences between these settings, we
can distill three elements of context-speciﬁc health care infrastructures
that inﬂuence the shape of genomics in routine health care delivery.
First, regulation and policy, such as the legal restrictions on clinical ge-
netics in theNetherlands or the regional allocation of funding tomedical
disciplines in the UK produce a broad frameworkwithinwhich genomic
medicine is established. Second, institutionalization of, for example, di-
agnosis andmonitoring in a consortium of university clinics in Germany
and monitoring speciﬁcally for mutation carriers in the Netherlands
have an impact on how robust the availability of particular services is.
Finally, standardization and guidelines, perhaps most prominent in the
central standard setting role of NICE in the UK, but equally important
in the more specialized context of a registry for hereditary tumors in
theNetherlands, speciﬁes how scientiﬁc evidence can and should be ap-
plied to individual clinical cases.
But while we ﬁnd similarmechanisms of translation vis-à-vis health
care infrastructures in each three of these countries, they shape up in
highly speciﬁc ways that speak to the sociocultural speciﬁcity of the in-
frastructures at stake. The particular conﬁgurations of actors and insti-
tutions that shape trajectories for genomics from bench to bedside
and beyond are rooted in both particular national histories and tradi-
tions of health care organization and chance events that steer develop-
ments in certain ways. Consider for example the establishment of the
German consortiumof university clinicswith the support of theGerman
Cancer Society and in response to policy statements by medical profes-
sional organization, the formation of a registry for hereditary tumors
largely independent from existing infrastructures in the Netherlands,
or the top-down, centralized role of NICE in the UK. These are very di-
vergent organizations that each produces the diagnostic guidelines for
particular national settings. In addition, an important area of difference
between these countries is the autonomy physicians have in setting out
a course of risk assessment andmonitoring for their patients and thede-
gree of inﬂuence external actors such as insurers and the state have on
whether these services get reimbursed. While medical doctors in Ger-
many appear to have a relatively large degree of autonomy in Germany,
their discretionary space is much more circumscribed in theNetherlands and especially through NICE and regional budgeting in
the NHS in the United Kingdom. At the same time, gaps and controver-
sies in service delivery are equally speciﬁc to each setting, as reﬂected in
the struggles between inpatient and outpatient delivery of genetic test-
ing in Germany; the contested distinction between familial and heredi-
tary risks in the Netherlands; and the regional differences in availability
of services in the UK. The contributions of translation to population
health thus depend to a signiﬁcant degree on national responses to
technical novelties.
These context-speciﬁc manifestations of genomics' contribution to
population health imply that the impact of infrastructures on transla-
tion cannot be seen as exclusively social. Just like translation processes
run in both directions between bench and bedside, clinical practices of
risk assessment and infrastructures of health care delivery mutually
shape each other. To understand the translation of novel medical inter-
ventions into routine health care, the process of translation therefore
has to be understood as socio-technical. Consequently, and even though
they largely rely on the same scientiﬁc evidence of familial and genetic
factors contributing to individual breast cancer risks, the three countries
discussed here turn familial breast cancer into something that is also
clinically different across borders. While risk assessment in all three
countries combines statistical risk calculation and genetic testing, the
balance between these methods may be signiﬁcantly different. In Ger-
many, there ismuchmore emphasis on identifyingwomenwho can un-
dergo a genetic test; in theNetherlands, genetic risks aremost explicitly
understood and treated as different from familial ones; and in the Unit-
ed Kingdom genetic testing is of lesser importance for deciding on fol-
low-up monitoring than statistical risk categories are. This is not to
say that all applications of genomics in health care in these countries
necessarily shape up like this; they may in fact be very different for
other diseases, where different actor conﬁgurations, regulations and
sets of standards and guidelines are involved (see e.g. (Aarden et al.,
2011)). Nevertheless, it suggests that the indicators of population health
that translation is expected to contribute to are affected by processes to
establish new technologies in health care as much as regulations, insti-
tutions and standards are. Deﬁnitions of health and disease change to-
gether with the incorporation of new diagnostics and therapeutics in
established routines.
Onemay argue that things are differentwith the advent of genomics
(as distinct from the largely genetic predispositions discussed here). For
one, it appears that in the years since the completion of the initial study
presented here, guidelines in these three countries have converged
somewhat (although that does not imply convergence of health care de-
livery). Moreover, both biological-technical and social-institutional di-
mensions of genomic medicine continue to undergo rapid and
interconnected transformations. New diagnostic techniques, including
next generation sequencing, as well as shifting perspectives on stability
and change in the genome are likely to complicate any straightforward
notions of ‘genetic predispositions’ (Lappe and Landecker, 2015). At the
same time, private industry and venture capital play an increasingly im-
portant role in the development of new medical technologies (Lehoux
et al., 2016), with as yet unclear consequences for health care delivery
infrastructures. Nevertheless, even the most recent development of
new diagnostic markers, sequencing tests and other new technologies
applied in the oncological ﬁeld similarly involves negotiation of techni-
cal, social and regulatory dimensions (Kohli-Laven et al., 2011; Nelson
et al., 2013). This means that the translation of new technologies to
health care delivery, as well as the delivery of care to particularly de-
ﬁned populations will continue to unfold in context speciﬁc ways,
with potential residues of how things are done at present.
In order to truly understand and be able to anticipate the translation
of genomics to health care in the interest of population health,we there-
fore need to attend to the speciﬁc mechanics of translation in different
medical-technological and infrastructural contexts. This implies that
translation in the interest of population health is a question that can nei-
ther exclusively be solved on the basis of scientiﬁc evidence, nor
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Genomic technologies and their translation to routine health care pres-
ent a number of challenges – both medical and organizational – of
which the exact breadth and depth are uncertain. As genomics promises
a personalization of health that intersects in complex ways with politi-
cal trends towards increased individual (ﬁnancial) responsibility for
obtaining medical care (Bella, 2010), the question of translation is par-
adoxically a question of collective choice. It requires attention to the
evolving knowledge base on the genomic dimensions of disease as
well as explicit and inclusive considerations of uncertainties and social
preferences and priorities regarding resource distribution. The transla-
tion of genomics from bedside to population health care delivery is con-
sequently an issue that requires informed democratic deliberation
(Bijker et al., 2009; Brown, 2009). Only through collective, balanced de-
liberation about the social as well as technical dimensions of translation
may genomics fully realize its promising potential for improving popu-
lation health.
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